Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 3
Submit an article Journal homepage
206
Views
6
CrossRef citations to date
0
Altmetric
Theme: Diabetes, Obesity & Metabolic Syndrome - Review

Dual antiplatelet therapy in patients with diabetes mellitus: special considerations

Piera Capranzano Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy
&
Davide Capodanno Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy. [email protected]
Pages 307-317 | Published online: 10 Jan 2014

References

  • Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 298(7), 765–775 (2007).
  • Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591), 937–948 (2007).
  • Osende JI, Badimon JJ, Fuster V et al. Blood thrombogenicity in Type 2 diabetes mellitus patients is associated with glycemic control. J. Am. Coll. Cardiol. 38(5), 1307–1312 (2001).
  • Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108(12), 1527–1532 (2003).
  • Davì G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357(24), 2482–2494 (2007).
  • Angiolillo DJ, Roffi M, Fernandez-Ortiz A. Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. Expert Rev. Cardiovasc. Ther. 9(6), 697–710 (2011).
  • Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in Type 2 diabetes: role of antiplatelet agents. Diab. Vasc. Dis. Res. 5(2), 138–144 (2008).
  • Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 31, 2501–2555 (2010).
  • Levine GN, Bates ER, Blankenship JC et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58(24), e44–e122 (2011).
  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
  • Mehta SR, Yusuf S, Peters RJ et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527–533 (2001).
  • Steinhubl SR, Berger PB, Mann JT 3rd et al.; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411–2420 (2002).
  • Sabatine MS, Cannon CP, Gibson CM et al.; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294(10), 1224–1232 (2005).
  • Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb. Haemost. 102(1), 7–14 (2009).
  • Angiolillo DJ. Antiplatelet therapy in Type 2 diabetes mellitus. Curr. Opin. Endocrinol. Diabetes. Obes. 14(2), 124–131 (2007).
  • Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 32(4), 531–540 (2009).
  • Hillegass WB, Brott BC, Dobbs JC, Papapietro SE, Misra VK, Zoghbi GJ. Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview. Vasc. Health Risk Manag. 7, 445–459 (2011).
  • Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123(7), 798–813 (2011).
  • Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353(22), 2373–2383 (2005).
  • Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25), 3156–3164 (2007).
  • Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308, 81–106 (1994).
  • Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86 (2002).
  • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8), 2430–2435 (2005).
  • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am. J. Cardiol. 97(1), 38–43 (2006).
  • DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56(12), 3014–3019 (2007).
  • Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167(15), 1593–1599 (2007).
  • Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336(7637), 195–198 (2008).
  • Davì G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in Type II diabetes mellitus. N. Engl. J. Med. 322(25), 1769–1774 (1990).
  • Guthikonda S, Lev EI, Patel R et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J. Thromb. Haemost. 5(3), 490–496 (2007).
  • Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37(8), 2153–2158 (2006).
  • Maree AO, Curtin RJ, Chubb A et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J. Thromb. Haemost. 3(10), 2340–2345 (2005).
  • Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345(25), 1809–1817 (2001).
  • Mehta SR, Bassand JP, Chrolavicius S et al.; CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N. Engl. J. Med. 363, 930–942 (2010).
  • Capodanno D, Patel A, Dharmashankar K et al. Pharmacodynamic effects of different aspirin dosing regimens in Type 2 diabetes mellitus patients with coronary artery disease. Circ. Cardiovasc. Interv. 4(2), 180–187 (2011).
  • Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P. Twice-daily dosing of aspirin improves platelet inhibition in whole blood in patients with Type 2 diabetes mellitus and micro- or macro-vascular complications. Thromb. Haemost. 106(3), 491–499 (2011).
  • Addad F, Chakroun T, Elalamy I et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int. J. Hematol. 92(2), 296–301 (2010).
  • Jneid H, Anderson JL, Wright RS et al.; 2012 Writing Committee Members. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 126, 875–910 (2012).
  • Kushner FG, Hand M, Smith SC Jr et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120(22), 2271–2306 (2009).
  • Steg PG, James SK, Atar D et al.; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33, 2569–2619 (2012).
  • Chen ZM, Jiang LX, Chen YP et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497), 1607–1621 (2005).
  • Sabatine MS, Cannon CP, Gibson CM et al.; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352(12), 1179–1189 (2005).
  • Bhatt DL, Fox KA, Hacke W et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354(16), 1706–1717 (2006).
  • Andersson C, Lyngbæk S, Nguyen CD et al. Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA 308(9), 882–889 (2012).
  • Angiolillo DJ, Bernardo E, Sabaté M et al. Impact of platelet reactivity on cardiovascular outcomes in patients with Type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol. 50(16), 1541–1547 (2007).
  • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505–1516 (2007).
  • Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J. Thromb. Haemost. 8(1), 37–42 (2010).
  • Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J. Am. Coll. Cardiol. 56(21), 1683–1692 (2010).
  • Angiolillo DJ, Fernández-Ortiz A, Bernardo E et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J. Invasive Cardiol. 16(4), 169–174 (2004).
  • Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am. J. Cardiol. 100(2), 203–205 (2007).
  • Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J. Am. Coll. Cardiol. 57(11), 1251–1263 (2011).
  • Price MJ, Endemann S, Gollapudi RR et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29(8), 992–1000 (2008).
  • Marcucci R, Gori AM, Paniccia R et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119(2), 237–242 (2009).
  • Geisler T, Grass D, Bigalke B et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J. Thromb. Haemost. 6(1), 54–61 (2008).
  • Hochholzer W, Trenk D, Fromm MF et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55(22), 2427–2434 (2010).
  • Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Am. Heart J. 155(1), 93.e1–93.e7 (2008).
  • Geisler T, Anders N, Paterok M et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30(2), 372–374 (2007).
  • Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb. Haemost. 100(1), 76–82 (2008).
  • Angiolillo DJ, Bernardo E, Ramírez C et al. Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol. 48(2), 298–304 (2006).
  • Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am. Heart J. 158(5), 784.e1–784.e6 (2009).
  • Ferreira IA, Mocking AI, Feijge MA et al. Platelet inhibition by insulin is absent in Type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 26(2), 417–422 (2006).
  • Ueno M, Ferreiro JL, Tomasello SD et al. Functional profile of the platelet P2Y12 receptor signalling pathway in patients with Type 2 diabetes mellitus and coronary artery disease. Thromb. Haemost. 105(4), 730–732 (2011).
  • Angiolillo DJ, Bernardo E, Zanoni M et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with Type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol. 58(1), 30–39 (2011).
  • Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 280(4), H1480–H1489 (2001).
  • Michno A, Bielarczyk H, Pawelczyk T, Jankowska-Kulawy A, Klimaszewska J, Szutowicz A. Alterations of adenine nucleotide metabolism and function of blood platelets in patients with diabetes. Diabetes 56(2), 462–467 (2007).
  • Guthikonda S, Alviar CL, Vaduganathan M et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J. Am. Coll. Cardiol. 52(9), 743–749 (2008).
  • Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6), 708–716 (2007).
  • Mehta SR, Tanguay JF, Eikelboom JW et al.; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748), 1233–1243 (2010).
  • Price MJ, Berger PB, Teirstein PS et al.; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097–1105 (2011).
  • Mega JL, Hochholzer W, Frelinger AL 3rd et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306(20), 2221–2228 (2011).
  • Capranzano P, Ferreiro JL, Angiolillo DJ. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Rev. Cardiovasc. Ther. 7(4), 361–369 (2009).
  • Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153(1), 66.e9–66.16 (2007).
  • Wiviott SD, Trenk D, Frelinger AL et al.; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116(25), 2923–2932 (2007).
  • Angiolillo DJ, Badimon JJ, Saucedo JF et al. A pharmacodynamic comparison of prasugrel vs high-dose clopidogrel in patients with Type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur. Heart J. 32(7), 838–846 (2011).
  • Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI-38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
  • Wiviott SD, Braunwald E, Angiolillo DJ et al.; TRITON-TIMI-38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 118(16), 1626–1636 (2008).
  • Roe MT, Armstrong PW, Fox KA et al.; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N. Engl. J. Med. 367(14), 1297–1309 (2012).
  • Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am. Heart J. 156(Suppl. 2), S10–S15 (2008).
  • Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev. Cardiovasc. Ther. 8(2), 151–158 (2010).
  • Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25), 2577–2585 (2009).
  • Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  • James S, Angiolillo DJ, Cornel JH et al.; PLATO Study Group. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur. Heart J. 31(24), 3006–3016 (2010).
  • Biondi-Zoccai G, Lotrionte M, Agostoni P et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int. J. Cardiol. 150(3), 325–331 (2011).
  • Hamm CW, Bassand JP, Agewall S et al.; ESC Committee for Practice Guidelines; Document Reviewers. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32(23), 2999–3054 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.